Incyte (ICY) Price & Analysis
ICY Stock Chart & Stats
- Day’s Range
- EUR 105.40 - EUR 108.25
- 52-Week Range
- EUR 77.60 - EUR 116.25
- Previous Close
- EUR 103.75
- Volume
- 2
- Average Volume (3M)
- 91
- Market Cap
- EUR 21.90B
- Enterprise Value
- EUR 20.85B
- Total Cash (Recent Filing)
- EUR 3.85B
- Total Debt (Recent Filing)
- EUR 37.41M
- Price to Earnings (P/E)
- 57.3
- Beta
- 0.09
- Next Earnings
- Feb 09, 2027
- EPS Estimate
- 1.71
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Broad-based Revenue Growth And Core-business Diversification
Growth is broadening beyond Jakafi, reducing reliance on a single established product and creating a more diversified commercial base. The 30% expansion in the core business, supported by several marketed medicines, strengthens the company’s ability to compound revenue over the next several quarters.
High-margin, Conservatively Financed Business
Very high gross margins provide substantial economic capacity to fund research, commercialization, and business development. Minimal leverage preserves financial flexibility and limits balance-sheet pressure, allowing Incyte to continue investing in its pipeline while retaining resilience if individual programs or products underperform.
Expanded Late-stage Pipeline And Regulatory Progress
A broad phase III portfolio and advancing regulatory reviews create multiple potential sources of future growth across oncology, hematology, and dermatology. This diversification improves the strategic runway beyond current products, while positive regulatory progress increases the probability of nearer-term commercial expansion.
Bears Say
Recent Free-cash-flow Deterioration
Although cash generation remains positive, the sharp TTM decline indicates that earnings are converting into cash less consistently than in the prior period. Continued volatility could constrain internally funded investment and make operating performance less predictable while the company advances several costly development programs.
Earnings And Operating-profitability Volatility
Revenue growth and strong gross margins have not translated into stable bottom-line performance across periods. The swings from near-breakeven results to strong profitability and back to a lower TTM margin suggest cost or mix pressure, making sustainable earnings power harder to assess over the medium term.
Jakafi Pricing Pressure And Pipeline Attrition
The gap between Jakafi demand and reported sales growth shows that pricing dynamics can dampen an important established revenue stream. Separately, discontinuing a phase III program removes a potential future opportunity, highlighting execution and commercial-prioritization risks within the pipeline.
Incyte News
ICY FAQ
What was Incyte’s price range in the past 12 months?
What is Incyte’s market cap?
When is Incyte’s upcoming earnings report date?
How were Incyte’s earnings last quarter?
Is Incyte overvalued?
Does Incyte pay dividends?
What is Incyte’s EPS estimate?
How many shares outstanding does Incyte have?
What happened to Incyte’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Incyte?
What is the TipRanks Smart Score and how is it calculated?
Incyte Stock Smart Score
Company Description
Incyte
Incyte Corporation is a biopharmaceutical firm engaged in the research, development, and global marketing of its own innovative therapies. Its current product offerings include JAKAFI, prescribed for myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that targets oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor utilized for chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. Beyond its marketed drugs, Incyte's pipeline features several promising candidates. Among its clinical-stage assets are ruxolitinib, targeting steroid-refractory chronic graft-versus-host disease (GVHD), and itacitinib, which is undergoing Phase II/III trials for newly diagnosed chronic GVHD. Pemigatinib is also being investigated for conditions such as bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and other tumor types. Further advancing its research, the company is developing Parsaclisib, currently in Phase II studies for follicular lymphoma, marginal zone lymphoma, and mantle cell lymphoma. Additionally, Retifanlimab is in Phase II development for multiple indications, including MSI-high endometrial cancer, Merkel cell carcinoma, anal cancer, and non-small cell lung cancer. Incyte maintains a broad network of strategic alliances with numerous pharmaceutical and biotech companies, including key partners like Novartis International Pharmaceutical Ltd., Eli Lilly and Company, and Agenus Inc., among many others. These collaborations extend to clinical trials, notably joint efforts with MorphoSys AG and Xencor, Inc., to evaluate a combination therapy involving tafasitamab, plamotamab, and lenalidomide for patients with recurrent or resistant diffuse large B-cell lymphoma and follicular lymphoma. Established in 1991, the corporation's main offices are situated in Wilmington, Delaware.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- William J. Meury
- Employees
- 2,844
- Website
- www.incyte.com
- Address
- 1801 Augustine Cut-Off, Wilmington, DE, 19803, US
Incyte (ICY) Earnings & Revenues
ICY Company Deck
ICY Earnings Call
Earnings Call SentimentPositive
The call was strongly positive, characterized by 14% quarterly revenue and net sales growth, broad-based product demand, raised full-year sales guidance, regulatory progress, and substantial expansion of the late-stage pipeline. The main negatives were the large Vega-related GAAP expense increase, pricing-related moderation in reported Jakafi growth, the discontinuation of the platinum-resistant ovarian cancer CDK2 study, and some pending clinical and regulatory milestones. Highlights significantly outweighed lowlights.
View all DE:ICY earnings summariesICY Net sales Breakdown
- 84.69% Product revenues, net
- 12.39% Product royalty revenues
- 2.92% Milestone and contract revenues
ICY Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 15 | 2 | 4 |
| Technical Analysis | 3 | 2 | 4 |
| Moving Averages | 12 | 0 | 0 |